[资料]【RCT报道】进展期鼻咽癌化放疗
这个帖子发布于 19 年零 242 天前，其中的信息可能已发生改变或有所发展。
【RCT报道】进展期鼻咽癌化放疗
8 randomized trials comparing chemotherapy plus RT with RT alone in locally advanced nasopharyngeal carcinoma. Chemothrapy led to a small, but significant, benefit for overall survival ans event-free survival. This benefit was essentially observed when chemotherapy was administered concomitantly with RT.
8组共1753名患者。同时行化疗+放疗可提高患者的总体生存率（OS）和无事件生存率（EFS）。但放疗前诱导化疗和放疗后辅助化疗效果仍不清楚。
International Journal of Radiation Oncology*Biology*Physics, Volume 64, Issue1, Pages 47-56 (1 Jan 2006)
Objectives: To study the effect of adding chemotherapy to radiotherapy (RT) on overall survival and event-free survival for patients with nasopharyngeal carcinoma.
Methods and Materials: This meta-analysis used updated individual patient data from randomized trials comparing chemotherapy plus RT with RT alone in locally advanced nasopharyngeal carcinoma. The log–rank test, stratified by trial, was used for comparisons, and the hazard ratios of death and failure were calculated.
Results: Eight trials with 1753 patients were included. One trial with a 2 × 2 design was counted twice in the analysis. The analysis included 11 comparisons using the data from 1975 patients. The median follow-up was 6 years. The pooled hazard ratio of death was 0.82 (95% confidence interval, 0.71–0.94; p = 0.006), corresponding to an absolute survival benefit of 6% at 5 years from the addition of chemotherapy (from 56% to 62%). The pooled hazard ratio of tumor failure or death was 0.76 (95% confidence interval, 0.67–0.86; p < 0.0001), corresponding to an absolute event-free survival benefit of 10% at 5 years from the addition of chemotherapy (from 42% to 52%). A significant interaction was observed between the timing of chemotherapy and overall survival (p = 0.005), explaining the heterogeneity observed in the treatment effect (p = 0.03), with the highest benefit resulting from concomitant chemotherapy.
Conclusion: Chemotherapy led to a small, but significant, benefit for overall survival and event-free survival. This benefit was essentially observed when chemotherapy was administered concomitantly with RT.
8 randomized trials comparing chemotherapy plus RT with RT alone in locally advanced nasopharyngeal carcinoma. Chemothrapy led to a small, but significant, benefit for overall survival ans event-free survival. This benefit was essentially observed when chemotherapy was administered concomitantly with RT.
8组共1753名患者。同时行化疗+放疗可提高患者的总体生存率（OS）和无事件生存率（EFS）。但放疗前诱导化疗和放疗后辅助化疗效果仍不清楚。
International Journal of Radiation Oncology*Biology*Physics, Volume 64, Issue1, Pages 47-56 (1 Jan 2006)
Objectives: To study the effect of adding chemotherapy to radiotherapy (RT) on overall survival and event-free survival for patients with nasopharyngeal carcinoma.
Methods and Materials: This meta-analysis used updated individual patient data from randomized trials comparing chemotherapy plus RT with RT alone in locally advanced nasopharyngeal carcinoma. The log–rank test, stratified by trial, was used for comparisons, and the hazard ratios of death and failure were calculated.
Results: Eight trials with 1753 patients were included. One trial with a 2 × 2 design was counted twice in the analysis. The analysis included 11 comparisons using the data from 1975 patients. The median follow-up was 6 years. The pooled hazard ratio of death was 0.82 (95% confidence interval, 0.71–0.94; p = 0.006), corresponding to an absolute survival benefit of 6% at 5 years from the addition of chemotherapy (from 56% to 62%). The pooled hazard ratio of tumor failure or death was 0.76 (95% confidence interval, 0.67–0.86; p < 0.0001), corresponding to an absolute event-free survival benefit of 10% at 5 years from the addition of chemotherapy (from 42% to 52%). A significant interaction was observed between the timing of chemotherapy and overall survival (p = 0.005), explaining the heterogeneity observed in the treatment effect (p = 0.03), with the highest benefit resulting from concomitant chemotherapy.
Conclusion: Chemotherapy led to a small, but significant, benefit for overall survival and event-free survival. This benefit was essentially observed when chemotherapy was administered concomitantly with RT.
2 收藏点赞
